Karen Carlisle-Bond
Family · Gulfport, MSNPI 1700521325
Payments from drug & device makers
Across 84 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tersera Therapeutics LLC$269
- Merck$202
- Exelixis Inc.$168
- Novartis$153
- Eisai Inc.$149
- Sanofi$144
- plus $738 from 16 others
What the payments were for
- Food & beverage$1,62489%
- Education$19911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tersera Therapeutics LLC | 10 | $269 |
| Merck | 10 | $202 |
| Exelixis Inc. | 5 | $168 |
| Novartis | 8 | $153 |
| Eisai Inc. | 8 | $149 |
| Sanofi | 8 | $144 |
| AstraZeneca | 7 | $133 |
| Johnson & Johnson(2 entities) | 6 | $123 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Lilly USA, LLC | 4 | $78 |
| Bayer | 3 | $64 |
| Incyte Corporation | 3 | $52 |
| Puma Biotechnology, Inc. | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Coherus Oncology, Inc. | 1 | $19 |
| Amgen | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| EMD Serono, Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Gilead | 1 | $17 |
| G1 Therapeutics, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$1,823 in reported general payments places this provider in the 75th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $9,171 |
| Celecoxib | 74 | $1,621 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 126 | $875 |
| Meloxicam | 244 | $617 |
| Tizanidine Hcl | 140 | $600 |
| Tramadol Hcl | 64 | $303 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 31 | $242 |
| Cyclobenzaprine Hcl | 37 | $241 |
| Methylprednisolone | 25 | $160 |
| Doxycycline Hyclate | 16 | $108 |
| Ibuprofen | 20 | $74 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $47 |
| Hydromorphone Hcl | 37 | $38 |
Paid to pharmacies, not to this prescriber.
Other family in Gulfport
- Stephanie RomeroGulfport$28K
- Ashley HouseGulfport$14K
- Chaeleena LaddGulfport$14K
- Justine HuntGulfport$12K
- Laura StevensGulfport$11K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.